Last reviewed · How we verify

NCT05565430

Vocal Cord Responses During Hyperventilation in Normal Individuals and in Mild and Severe Asthmatics.

Completed Last updated 8 May 2025
What this trial tests

trial testing Acute Hyperventilation in Hyperventilation in 24 participants. Completed in 10 February 2025.

Timeline
1 June 2018
Primary endpoint
10 February 2025
10 February 2025

Quick facts

Lead sponsorMonash Medical Centre
StatusCompleted
Study typeOBSERVATIONAL
Enrollment24
Start date1 June 2018
Primary completion10 February 2025
Estimated completion10 February 2025
Sites1 location across Australia

Drugs / interventions tested

Conditions studied

Sponsor

Monash Medical Centre — full company profile →

Who can join

Adults 18 to 65, any sex, with Hyperventilation or Larynx. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Investigators aim to: 1. Study the effect of hyperventilation on the development of paradoxical vocal cord movement (PVCM) in healthy individuals and in patients with mild and severe asthma, 2. Relate PVCM to airway symptoms and measurements of intra- and extra-thoracic airway hyperresponsiveness (ET-AHR), 3. Evaluate the effects of inhaled anti-cholinergic agents on PVCM induced by hyperventilation. Hypotheses: 1. In health PVCM will not occur in response to hyperventilation, 2. In asthma PVCM will occur in response to hyperventilation, 3. Airway symptoms and ET-AHR will develop in parallel with PVCM, 4. Inhaled anticholinergic agents will prevent PVCM induced by hyperventilation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05565430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing